Glaukos Corporation has gained 8% in a week and drawn a flurry of upward analyst revisions — yet the stock enters its July 29 earnings window with short sellers still firmly in place and a key reimbursement decision hanging over the bull case.
The analyst activity this week is notably one-directional. Citigroup raised its target to $175 this morning — the second lift in four weeks after bumping from $140 to $162 in mid-June. HC Wainwright initiated with a Buy and a $168 target on Monday. Piper Sandler reiterated Overweight at $165 last week. Every recent action is a Buy or Overweight, with no downgrades. The consensus mean target is $159, leaving just 6% implied upside against the current $150.65 close — modest headroom after a 20% one-month run. The bull case centers on iDose TR and the Epioxa launch driving durable revenue growth. The bear case is specific: a draft Medicare local coverage determination could restrict iDose procedures by roughly 25% if it treats prior laser therapy as a prerequisite, and that uncertainty hasn't gone away. The stock is priced for the bull case; the LCD risk is what the Street is wrestling with into the print.
Short positioning has eased slightly from last week's peak but remains meaningful. Short interest sits at 7.8% of free float — down about 1.5% on the week but still nearly 30% higher than a month ago, consistent with the rebuilding trend flagged in the prior note. The borrow market remains entirely untroubled. Availability is loose at 1,572%, meaning the lending pool dwarfs the current short position by a wide margin. Cost to borrow is 0.42% — low and stable, down roughly 10% on the week. Shorts are present and their conviction hasn't cracked, but there is no mechanical pressure to cover. The put/call ratio at 8.7 looks alarming at first glance but has been running in this elevated range since late June; the 20-day mean is 7.8 and the z-score is only 0.4, so the current reading reflects the structural character of GKOS options activity rather than a fresh defensive surge. Overall, positioning is watchful but not extreme in either direction.
The insider register is worth noting. All recent trades in the data are sells — CEO Thomas Burns, President/COO Joseph Gilliam, and CFO Alex Thurman each sold shares across April, May, and June, with the COO transacting for over $2.8 million on May 1. Net insider activity over the past 90 days reflects nearly $9.7 million of net selling across roughly 74,000 shares. These are small percentages of total ownership, and some will be plan-driven, but the consistent direction across C-suite names is a data point worth keeping alongside the bullish analyst chorus.
Prior earnings reactions have been asymmetric. The most recent Q1 print on April 29 delivered a 20% single-day gain, with the stock holding most of it into the following week. The May event was a 6% one-day decline with a recovery to +11% over five days. Two sharp moves in opposite directions heading into July 29 is the pattern to carry into the next print — rather than a gentle drift, GKOS tends to gap materially on results, and the LCD resolution timeline will likely determine which direction that gap runs.
What to watch into July 29: any update on CMS's final LCD ruling on iDose TR is the single most consequential event between now and earnings — a favorable revision removes the primary bear case, while confirmation of the draft policy would test whether the Street's Buy chorus can survive a meaningful cut to volume assumptions.
See the live data behind this article on ORTEX.
Open GKOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
